RXST
$6.44-0.30 (-4.45%)
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States.
Recent News
How The RxSight (RXST) Investment Story Is Shifting With New Guidance And CFO Transition
RxSight’s updated fair value estimate has shifted from US$10.17 to US$10.06, a small adjustment that signals a slightly more restrained price target without a major reset. Analysts tying this move to the new 2026 revenue guidance of US$120.0m to US$135.0m, recent Q4 updates, and the CFO transition are largely keeping the stock in neutral territory while they refresh their models. As you read on, you will see how these pieces fit together and what to watch as the RxSight story continues to...
How The RxSight (RXST) Investment Story Is Shifting With New Guidance And CFO Change
RxSight’s blended fair value estimate has edged down to US$10.17 from US$10.39, reflecting a modest recalibration in the latest round of research updates. Analysts are largely sticking with neutral ratings and fine tuning their targets in a tight band, as they weigh softer 2026 revenue guidance against a slightly firmer revenue trajectory for 2025 and a new CFO stepping into the role. Read on to see how you can track these shifting targets and what they might mean for your own view on...
RxSight, Inc. Q4 2025 Earnings Call Summary
Moby summary of RxSight, Inc.'s Q4 2025 earnings call
RxSight Q4 Earnings Call Highlights
RxSight (NASDAQ:RXST) reported fourth-quarter 2025 revenue of $32.6 million, down 19% year-over-year, driven primarily by lower Light Delivery Device (LDD) sales following an unusually strong prior-year comparison. Management said results were consistent with the company’s January pre-announcement a
RxSight Inc (RXST) Q4 2025 Earnings Call Highlights: Navigating Challenges with Strategic ...
Despite a dip in quarterly revenue, RxSight Inc (RXST) focuses on global growth and innovation to drive future success.